Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Biotechnology

Healthcare
$8.86 +2.49%

+$0.22 today

Market cap
$595.76M
Beta
1.48
P/E (TTM)
-8.6
EPS (TTM)
-$0.74
52W Low $5.82High $12.86

Volume 0.16M

Average 0.05M

EPRX.TO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$88.67K, compared with -$46.84K a year earlier. Trailing-twelve-month gross profit was -$281.1K.

Context

  • Gross profit grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$88.67K or moves back toward the trailing-twelve-month quarterly average of -$70.28K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$88.67K-19.9% QoQ
Last fiscal yearDec 2025
-$241.88K-48.0% YoY
LTMMar 2026
-$281.1K-30.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.3%——
1 year-48.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

Mixed currencies · from the income statement

Latest · FY2025
(241.88K) USD
Year-over-year change
-48.0%

Gross Profit vs competitors

How EPRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -30.3% is the 6th highest of 8, against a peer median of -7.5%.
EPRX.TO Competitors
Gross Profit for EPRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DR.TOMedical Facilities CorporationLTM Mar 2026$136.02M USD-32.2%-29.5%44.5%
TSND.TOTerrAscend Corp.LTM Mar 2026$133.27M USD-10.0%+3.6%50.9%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$73.53M CAD-7.5%—23.6%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$47.19M USD+69.1%+204.4%92.2%
PRN.TOProfound Medical Corp.LTM Mar 2026$13.33M USD+74.9%+56.6%71.0%
HBP.TOHelix BioPharma Corp.LTM Apr 2026-CA$5K CAD+37.5%——
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026-$281.1K USD-30.3%——
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-CA$8.41M CAD-113.3%—3.1%
Peer median (excluding EPRX.TO) —-7.5%+30.1%47.7%

Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue111.53K193.27K158.05K163.47K241.88K
Gross Profit(111.53K)(193.27K)(158.05K)(163.47K)(241.88K)
Gross Margin—————
Research & Development10.17M17.58M21M15.17M21.51M
Selling, General & Admin8.2M5.81M7.37M10.92M17.1M
Operating Expenses18.38M23.38M28.37M25.54M38.86M
Depreciation & Amortization111.53K193.27K158.05K163.47K241.88K
EBITDA(21.96M)(22.14M)(28.16M)(23.43M)(38.86M)
EBITDA Margin—————
Operating Income(18.47M)(23.58M)(27.78M)(25.71M)(39.11M)
Operating Margin—————
Interest Income65.73K569.32K876.96K1.1M1.44M
Interest Expense1.3M1.59M1.19M913.1K0
Other Income / Expenses(4.9M)(341.09K)(1.08M)1.2M(155.19K)
Income Before Tax(23.37M)(23.92M)(28.93M)(24.51M)(39.26M)
Pre-Tax Margin—————
Income Tax Expense00(67.51K)1.72K19.42K
Net Income(22.99M)(23.26M)(28.15M)(24.28M)(39.25M)
Net Margin—————
EPS (Basic)(1.61)(1.21)(1.19)(0.72)(1.05)
EPS (Diluted)(1.61)(1.21)(1.19)(0.72)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.